(Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2017	Dec. 30, 2016	Sep. 30, 2016	Aug. 31, 2016	Feb. 01, 2016	Aug. 31, 2014
Questcor Pharmaceuticals, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability	$ 111.8	$ 124.7				$ 195.4
Hemostasis Products
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration					$ 52.0
Stratatech [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration				$ 54.9
Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	246.4	250.5
Recurring | Contingent Consideration | Questcor Pharmaceuticals, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	250.5
Payments	(25.0)
Business Combination, Contingent Consideration, Accretion	5.3
Fair value adjustment	(41.4)
Recurring | Contingent Consideration | Total Acquisitions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Ending balance	246.4
Level 3 | Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	246.4	250.5
Level 3 | Recurring | Stratatech [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability		55.7	$ 53.5
Level 3 | Recurring | Contingent Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances	57.0
Raplixa [Member] | Level 3 | Recurring | Hemostasis Products
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	7.0	58.9
PreveLeak [Member] | Level 3 | Recurring | Hemostasis Products
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability	$ 17.1	$ 11.2